Skip to main content
All lobbying filings

FORBES-TATE

Lobbying for GENENTECH · A biotechnology corporation

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income · posted Apr 18, 2026

Official filing document

 Lobbying activity 6
Copyright/Patent/Trademark

Intellectual property and process patent related issues.

Medicare/Medicaid

Issues related to Medicare and Medicaid coverage and reimbursement; Issues pertaining to 340B; Issues related to drug importation; Issues related to prescription drug pricing; Issues related to the International Pricing Index for Medicare Part D; Issues related to prescription drug user fee agreement; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to pharmacy benefit managers; Issues related to the Medicaid Drug Rebate Program.

Taxation/Internal Revenue Code

Issues related to international tax and R&D amortization credit in the Tax Cuts and Jobs Act (PL 115-97); Issues related to tax; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Manufacturing

Issues regarding the Center for Medicare and Medicaid Innovation; Issues related to the implementation of the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Budget/Appropriations

Issues related to funding of the strategic national stockpile; Issues related to the Tax Cuts and Jobs Act (PL 115-97); Issues related to the Medicaid Drug Rebate Program.

Health Issues

Issues related to the 340B Drug Pricing Program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem